PTAB challenges

Proceedings overview

A single AIA trial proceeding, IPR2026-00176, has been filed against US patent 12221638. This proceeding was denied institution, meaning the PTAB did not proceed to a full trial. This outcome strengthens the patent's defensive posture as its claims have withstood a challenge at the institution phase.

IPR2026-00176 — Halozyme, Inc. v. Alteogen Inc.

• Type: Inter Partes Review
• Filed: 2025-12-10
• Status: Institution Denied. The U.S. Patent Tribunal (PTAB) rejected the petition to initiate inter partes review.
• Judge panel: The specific Administrative Patent Judge (APJ) panel for this proceeding is not publicly available from the provided information. Records indicate a "Pending Judge Assignment" as of 2025-12-16.
• Petition grounds: Halozyme, Inc. challenged US Patent No. 12,221,638, which is a manufacturing patent for a method of producing recombinant hyaluronidase, targeting its novelty and progressiveness based on prior art and public literature. The specific claims challenged and the statutory basis (§ 102 / § 103) were not detailed in the available information, beyond a general challenge to "at least one claim".
• Institution decision: Denied on 2026-05-15. The PTAB determined that Halozyme's petition failed to demonstrate a "reasonable possibility of invalidating at least one claim," concluding that the prior art and public literature presented did not sufficiently show the possibility of destroying the novelty or progressiveness of Alteogen's patent. An Alteogen official stated that this was a substantive review of the prior technology and invalidity claims, not a simple procedural dismissal.
• Final Written Decision: Not applicable, as institution was denied.
• Settlement / termination: Not applicable.
• Appeal: Not applicable, as institution was denied. Decisions denying institution are generally non-appealable.
• Defensive value: This decision provides significant defensive value for Alteogen. The patent owner successfully defended against a direct challenge from a competitor, Halozyme, at the institution stage. This means all claims of US12221638 remain unadjudicated and presumed valid by the PTAB against the specific prior art and arguments raised in this petition, making future IPR challenges on similar grounds significantly more difficult for the same petitioner.

Strategic summary

US patent 12221638 has faced one AIA trial proceeding, IPR2026-00176, filed by Halozyme, Inc. The PTAB denied institution of this IPR on 2026-05-15. Consequently, all claims of US12221638 remain UNTESTED in a full PTAB trial. No claims have been canceled or invalidated through an AIA proceeding, and all claims are considered SUSTAINED as issued by the USPTO.

Regarding estoppel, the denial of institution for IPR2026-00176 generally means that statutory estoppel under 35 U.S.C. § 315(e)(2) does not apply to the petitioner (Halozyme, Inc.) or its privies. This is because a full trial was not instituted, and thus no final written decision on the patentability of claims was issued. Therefore, the specific prior art grounds raised in Halozyme's petition could theoretically still be raised in district court litigation by Halozyme, though the PTAB's finding of "no reasonable likelihood of success" may serve as a practical deterrent. All other prior-art grounds that could have been raised in an IPR petition are also still available to other potential challengers not in privity with Halozyme.

The current PTAB activity on US12221638 shows no discernible pattern of repeated challenges or aggressive appeals by the patent owner. Only one IPR has been filed, and it resulted in a favorable outcome for the patent owner, Alteogen, Inc., with institution being denied. This indicates that Alteogen has successfully defended its patent against an initial validity challenge from a competitor, suggesting the patent is robust against the arguments presented.

Recommended next steps

As a defendant facing assertion of US patent 12221638, it is important to note that all claims of the patent are currently SUSTAINED and have not been invalidated by the PTAB. The denial of institution in IPR2026-00176 means that the specific arguments and prior art presented by Halozyme, Inc. were deemed insufficient to establish a reasonable likelihood of success for invalidating any claim.

Since institution was denied, there is no Final Written Decision to link to. However, the decision denying institution for IPR2026-00176 (likely issued by the Director of the USPTO or a delegated panel on 2026-05-15) would be the key document. It is advisable to review the full institution denial decision to understand the specific reasoning and the prior art found insufficient. This will inform whether a new IPR petition, perhaps on different grounds or with stronger arguments, could be viable. The USPTO's PTAB Decisions portal or the Unified Patents portal (for IPR2026-00176) may contain the full decision.